Advanced
Genetic Screening
54 cancer genes and a personalised pharmacogenomics report. Our most comprehensive genetic test. In-clinic only in London. £1,300.
Cared for over 15,000 patients
Established 2016
What’s Included
54 Gene Cancer Panel
✓ 54 inherited cancer risk genes tested
✓ Covers breast, ovarian, bowel, prostate, pancreatic, melanoma and other cancer types
✓ ISO 15189 and CAP accredited laboratory
✓ Results in approximately four weeks
✓ Written results report
✓ GP results consultation included
✓ GP letters and referrals as needed
21 Gene Pharmacogenomic Panel
✓ 21 pharmacogenomics genes tested
✓ Covers statins, antidepressants, pain relief, anaesthetics, blood thinners and chemotherapy agents
✓ Personalised written report to keep and share with prescribing doctors
✓ Relevant for life, not just current medications
Why Genetic Testing Matters
Family History of Cancer
If a close relative was diagnosed with cancer, particularly at a young age, you may carry an inherited gene mutation without knowing it.
Your full genetic risk
Around 95% of people with an inherited cancer gene mutation in the UK have never been tested. Knowing your risk changes what you can do about it.
GP-supported throughout
Every result is reviewed with your Coyne Medical GP. You will never receive a report and be left to interpret it alone. Based at our Fulham clinic in London SW6.
Accredited laboratories
All testing is carried out by specialist laboratories accredited to CAP and ISO 15189 standards; the highest standards in clinical genetics.
How It Works
Step One
GP consultation
Your consultation takes place at our Fulham clinic. Your GP takes you through your family history, explains what both panels cover, and collects your blood sample.
Step Two
Your Sample
Your blood sample is sent directly to our accredited specialist laboratory. Results are ready in approximately four weeks.
Step Three
Your Results
You meet your GP to go through both reports in full. Your pharmacogenomics report is yours to keep and share with any prescribing doctor.
What the test covers
54 cancer genes. 21 gene pharmacogenomics.
Breast cancer
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53
Breast and ovarian cancer
BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, ATM, CHEK2, MLH1, MSH2, MSH6, EPCAM, PTEN, STK11, TP53, BARD1, DICER1, SMARCA4
Bowel and Lynch syndrome
APC, AXIN2, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, POLD1, POLE, PMS2, SMAD4
Prostate cancer
ATM, BRCA1, BRCA2, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, TP53
Pancreatic cancer
APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, TP53, VHL
Gastric cancer
CDH1, MLH1, MSH2
Melanoma and skin cancer
BAP1, CDKN2A, PTEN
Renal cancer
BAP1, FH, FLCN, MET, SMARCA4, SMARCB1, VHL
Neuroendocrine and paraganglioma
MEN1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, MAX
Less common hereditary syndromes
CDC73, DICER1, KIT, NF2, PDGFRA, PTCH1, RB1, SMARCB1, STK11, TSC1, TSC2, WT1
Pharmacogenomic panel
ABCG2, CACNA1S, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, G6PD, HLA-A, HLA-B, IFNL3, MT-RNR1, NUDT15, POR, RYR1, SLCO1B1, TPMT, UGT1A1, VKORC1
What Your Results Mean
Negative result
No pathogenic variant was found in the 54 genes tested. This is the most common outcome and, for most people, a reassuring one. You will still receive a written report with recommendations for ongoing screening.
Positive result
A variant with established clinical significance has been found. Your GP will explain what this means for your cancer risk and agree next steps, which may include enhanced surveillance, risk-reduction options, or specialist referral. Only clinically actionable variants are reported.
Your pharmacogenomics report
A personalised written document setting out how your genetics affect your response to the medications covered by the panel. It is not a diagnosis and it does not replace prescribing advice from your doctor. It is information your doctor can use to make better prescribing decisions for you, now and in the future. You receive a copy to keep and share with any prescribing doctor you see.
Why We Built This
Our co-founder, Dr Lucy Hooper, discovered her own PALB2 gene mutation while researching genetic screening for her patients. With a lifetime breast cancer risk of over 60%, she chose risk-reducing surgery, bringing her risk to under 5%.
Her experience is not unusual. What is unusual is that she knew to look. Most people in the same position never get the chance to make that choice, because they are never offered the test.
That is why genetic cancer screening is central to everything we do at Coyne Medical. Not as an add-on or an afterthought, but as one of the most important things we can offer the people who come to us.
Frequently Asked Questions
Inherited cancer gene testing analyses your DNA to identify variants in specific genes that are associated with a significantly higher lifetime risk of developing certain cancers. It is different from cancer screening tests such as a multi-cancer early detection blood test, which look for signs that cancer may already be present. Genetic testing tells you about your inherited risk before any cancer develops, allowing you to make informed decisions about surveillance, prevention, and lifestyle. The two types of testing are complementary rather than alternatives to one another.
The Inherited Cancer Risk Panel tests 35 cancer genes using a saliva sample and is available at home or in clinic from £650. The Advanced Genetic Screen tests 54 cancer genes using a blood sample taken in clinic, and adds a 21 gene pharmacogenomics panel that analyses how your body processes common medications. It is our most comprehensive genetic test and is available in clinic only at £1,300.
The Association of British Insurers and the British Medical Association have agreed on a set of questions that insurers can ask your GP when you apply for life insurance. Your GP will be asked about any medical condition you have suffered in the past or are currently experiencing that may reduce your life expectancy. They are also allowed to ask about your family history. They are not allowed to ask or request the results of any predictive genetic testing. The only exception in the UK applies if you are applying for life insurance over £500,000 and you have previously taken a predictive genetic test for Huntington’s Disease. Only in this circumstance do you need to disclose the result if asked. This exception does not apply to any of the genes tested in this panel. If you have a strong family history of breast cancer and your result is negative, it may be in your interest to disclose this voluntarily. You are never obliged to, but some people choose to. You can read more about the ABI code on the Association of British Insurers website.
A positive result means that a pathogenic variant has been identified in one of the 35 genes tested. Your GP will arrange a results consultation to explain what this means for your specific cancer risk, which types of cancer are associated with the variant found, and what the recommended options are. These may include enhanced surveillance such as annual MRI for high-risk BRCA carriers, medication options such as risk-reducing chemoprevention, or surgical risk reduction, depending on the gene and your individual circumstances. Our GPs can guide you into the appropriate NHS or private clinical pathway and will provide letters for any first-degree relatives who may wish to consider testing.
A negative result means that no pathogenic variant was detected in the 35 genes included in this panel. This is a clinically meaningful and, for most people, reassuring finding. It significantly reduces the likelihood that you carry a high-risk inherited variant in these specific genes. It does not eliminate all genetic cancer risk, since there are genes beyond this panel and non-genetic factors that also influence cancer risk. Your GP will discuss what appropriate ongoing cancer surveillance looks like for you based on your personal and family history.
Results are returned by the laboratory in approximately four weeks from sample receipt. For the at-home test, please allow additional time for kit delivery to you and return postage. We will contact you to schedule your results consultation as soon as your results arrive with us. The time from booking to receiving your results will typically be between five and six weeks for the at-home option and approximately four to five weeks for the in-clinic option.
Not necessarily. A negative result means that you have not inherited the specific variant being looked for in the genes on this panel. However, if a blood relative has already tested positive for a variant, that result is specific to them and their branch of the family. A negative result in one family member does not tell you whether other relatives carry the same variant. If a variant has been identified elsewhere in your family, targeted testing for that specific variant may be more appropriate than this full 35-gene panel. Your GP can advise on the best approach based on your family history.
Yes. The at-home 35 gene inherited cancer risk panel can be added to our Advanced Health Screening package for £650, or combined with a Multi-Cancer Early Detection blood test for a combined add-on price of £1,900. Inherited cancer gene testing is included as standard in our Ultimate Health Screening package, which also includes a 55 gene panel rather than 35 genes. If you are considering health screening alongside genetic testing, a Discovery Call with one of our GPs is a good starting point to identify the combination that best fits your needs.
All genetic analysis for the Advanced Genetic Screen is carried out by CeGaT, a specialist genetic laboratory based in Germany. CeGaT holds ISO 15189 and CAP accreditation and is one of the leading genetic diagnostic laboratories in Europe, trusted by hospitals and research institutions internationally.
We take the security of your genetic information extremely seriously. Your results are shared securely through our patient portal and your genetic data is never sold or shared with any third party, including insurers, employers or government bodies. The specialist laboratories we work with operate under strict rules governing the privacy of sensitive genetic data. You will be asked to consent to their receiving your sample and data before testing begins, and you may choose to opt out of any anonymised research use of your data.
Consumer DNA tests use a method called genotyping, which looks at common genetic variants and is designed for ancestry and general interest purposes. Our testing uses full-gene sequencing and deletion and duplication analysis via next-generation sequencing technology. This is the most accurate method available for identifying clinically significant inherited cancer gene variants. Consumer tests are not designed to guide medical decisions and should not be used for that purpose. All results from the Advanced Genetic Screen are reviewed with your Coyne Medical GP, who will explain what your findings mean and agree next steps with you.
No. The Advanced Genetic Screen requires a blood sample which is collected at our Fulham clinic during your GP consultation. If you would prefer an at-home option, our Inherited Cancer Risk Panel uses a saliva sample and can be taken at home from £650.
No. The pharmacogenomics report is relevant whether you are currently on medication or not. Many people are not yet on the medications covered by the panel but will be at some point in their lives. Having your results documented in advance means your prescribing doctor can access that information when it becomes relevant, potentially avoiding side effects or ineffective treatments before they happen.
Your pharmacogenomics report is a written document you receive as part of your results. You can share it directly with any GP, specialist or prescribing doctor. We recommend keeping a copy accessible and mentioning it whenever a new medication is prescribed. Your Coyne Medical GP can also write to other doctors on your behalf if helpful.
Looking for a simpler option?
The Inherited Cancer Risk Panel tests 35 clinically significant cancer genes using a saliva sample. Available at home or in clinic. From £650.
Talk to a GP first.
Book a 30-minute Discovery Call with one of our GPs. We will talk through your history, your concerns and your goals, and help you decide which test is right for you. The £250 fee is fully credited against any test or package you go on to book.